First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
Lee KH, Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K.
Lee KH, et al. Among authors: yoshida t.
Lung Cancer. 2025 Jan 25;201:108109. doi: 10.1016/j.lungcan.2025.108109. Online ahead of print.
Lung Cancer. 2025.
PMID: 39893774
Free article.